Loading clinical trials...
Loading clinical trials...
Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine
Conditions
Interventions
azacitidine
laboratory biomarker analysis
Locations
1
United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
April 1, 2010
Primary Completion Date
December 1, 2013
Last Updated
May 24, 2017
NCT01822015
NCT01523223
NCT02122081
NCT00119366
NCT00352365
NCT00536601
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions